The Kir6.1/2-Sur2A/B antagonist zoledronic acid showed instead higher case report numbers for breast > malignant neoplasm > prostate > lung neoplasm malignant > myelodysplastic syndrome > bladder > renal > ovarian > cancers and lower number of cancer cases for other cancer types including pancreatic carcinoma (Table 4). This evidence concerns the gene KCNJ8 and cancer.